Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, Journal of clinical oncology, vol.15, issue.6, pp.2403-2413, 1997. ,
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, New England Journal of Medicine, vol.364, issue.19, pp.1817-1825, 2011. ,
DOI : 10.1056/NEJMoa1011923
URL : https://hal.archives-ouvertes.fr/hal-00598658
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer???A GERCOR Study, Journal of Clinical Oncology, vol.24, issue.3, pp.394-400, 2006. ,
DOI : 10.1200/JCO.2005.03.0106
Final results and subgroup analyses of the phase III CAIRO3 study: maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC), J Clin Oncol, vol.32, issue.3504, p.5, 2014. ,
Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy, J Clin Oncol, vol.32, issue.4132, pp.5-2014 ,
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer, Journal of clinical oncology, vol.20, issue.1, pp.160-164, 2002. ,
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer, Journal of clinical oncology, vol.27, issue.33, pp.5513-5518, 2009. ,
Phase II Study of oral capecitabine in patients with advanced or metastatic pancreatic cancer, J Clin Oncol, vol.20, pp.160-164, 2001. ,
Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. Clinical breast cancer, pp.857-860, 2007. ,
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature, Annals of Oncology, vol.16, issue.8, pp.16-1289, 2005. ,
DOI : 10.1093/annonc/mdi253
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. The lancet oncology, pp.521-529, 2010. ,
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group, Journal of Clinical Oncology, vol.25, issue.15, pp.25-1960, 2007. ,
DOI : 10.1200/JCO.2006.07.9525
Phase II trial of erlotinib plus capecitabine as first-line treatment for 1, Cancer statistics CA: a cancer journal for clinicians, vol.64, issue.1, pp.9-29, 2014. ,
CA: a cancer journal for clinicians, Global cancer statistics, vol.61, issue.2, pp.69-90, 2011. ,
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening?a report from the, Journal of Clinical Oncology, vol.26, issue.2, pp.313-325, 2008. ,
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, New England Journal of Medicine, vol.364, issue.19, pp.1817-1825, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00598658
Progression Free Survival OS: Overall Survival MPC: Metastatic Pancreatic Cancer ECOG: Eastern Cooperative Oncology Group PS: Performans Status BMI: Body Mass Index CT: Computerized Tomography TTF: Time to Treatment Failure US: United States QOL: Quality Of Life NSCLC: Non-Squamous Cell Lung Cancer ORR : Objective Response Rate ,